Most of Globus Medical’s revenue comes from the United States, and the rest comes from its international segment. In 3Q17, the United States contributed $125.9 million.
Of the 13 analysts covering Globus Medical in February 2018, seven of them have given the stock a “buy” or higher rating. Five analysts have given it a “hold.”
Through MiMedx’s donor program, a mother scheduled to deliver a baby by C-section can donate her placental tissue rather than leave it as medical waste.
Of the four analysts covering MiMedx Group in January 2018, three have given the stock a “buy” rating, and one analyst has given it a “strong buy” rating.
